Transaction expands Chancery's gold royalty portfolio as the Company progresses toward a planned public listing in H1 2026 ...
Palvella Therapeutics (PVLA) stock jumps as a Phase 3 trial for the company's lead asset, Qtorin rapamycin, hits key endpoints against a rare skin disorder. Read more here.
一部の結果でアクセス不可の可能性があるため、非表示になっています。
アクセス不可の結果を表示する